Natriumfluorid (F-18) Life Radiopharma (Sodium Fluoride (18f))

Sodium fluoride (18F), the active ingredient in Natriumfluorid (F-18) Life Radiopharma, is a radiopharmaceutical presented as a solution for injection for intravenous use. It enables PET imaging of bone turnover, aiding detection of skeletal metastases and evaluation of bone metabolism in oncology patients.

GNH USA supplies Natriumfluorid (F-18) Life Radiopharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and clinics worldwide. The company adheres to EU GMP standards and provides regulatory documentation for cross‑border procurement, ensuring timely delivery and quality assurance.

Natriumfluorid (F-18) Life Radiopharma is used in PET imaging of the skeletal system to assess bone turnover and metastatic disease. - Skeletal metastases detection: enables visualization of metastatic lesions in bone. - Bone metabolism evaluation: assesses turnover rates in various bone disorders. - Cancer staging: assists in determining the extent of bone involvement in oncologic patients.

Adverse reactions are generally mild and related to the injection or radiation exposure.

Common Side Effects: - Injection site pain: mild discomfort at the venipuncture site. - Nausea: transient feeling of queasiness. - Flushing or warmth: brief sensation of heat. - Headache: mild to moderate intensity. - Dizziness: temporary light‑headedness. - Mild allergic reaction: rash or itching.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic response requiring immediate medical attention. - Significant radiation‑induced tissue injury: unlikely but possible with high cumulative doses. - Severe hypotension: marked drop in blood pressure post‑injection. - Cardiac arrhythmia: irregular heart rhythm in susceptible individuals. - Persistent vomiting: prolonged emesis requiring intervention.

Use of Natriumfluorid (F-18) requires careful consideration of patient factors and handling procedures. - Pregnancy: safety unknown; avoid unless essential for maternal care. - Breastfeeding: unknown safety; weigh potential risks before use. - Renal impairment: monitor closely as fluoride is renally cleared. - Allergy history: assess for hypersensitivity to fluoride compounds. - Radiation safety: follow local regulations for handling and disposal of radioactive material. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential interactions may affect tracer distribution or radiation exposure.

Major Interactions (Avoid): - Calcium supplements or high‑calcium diet: can reduce tracer uptake in bone. - Concurrent administration of other radiopharmaceuticals: may cause overlapping radiation dose.

Moderate Interactions (Monitor Closely): - Bisphosphonates or other bone‑active agents: may alter fluoride incorporation. - Renal‑affecting drugs (e.g., NSAIDs, ACE inhibitors): may modify clearance. - Iodinated contrast agents used in CT: could interfere with PET image interpretation. - Anticonvulsants influencing bone metabolism: monitor imaging results.